Strides Pharma Science Limited has announced a strategic acquisition to bolster its presence in the Sub-Saharan Africa (SSA) region. The company, through its step-down subsidiary Strides Pharma International AG, has entered into definitive agreements with Sandoz AG, Switzerland, and its group entities for the acquisition and in-licensing of a portfolio of branded generic products.
The acquisition covers four significant markets: Western Sahara, Ghana, Nigeria, and Kenya. The portfolio includes multiple brands in the anti-infective, cardiovascular, and dermatology therapeutic segments, with several products generating annual sales exceeding US$1 million. This reflects their established brand equity and market demand.
Strides will fully acquire certain products and continue to market select products on behalf of Sandoz. To ensure uninterrupted availability, Strides will also enter into a Manufacturing and Supply Agreement with Sandoz for continued production and supply.
This acquisition is expected to position Strides as one of the top five pharmaceutical players in the SSA region by sales and among the top two in the represented market. The combination of Strides’ existing business and the new branded portfolio from Sandoz is anticipated to generate strategic synergies, enhancing market reach and strengthening therapeutic leadership.
The transaction, valued at an initial consideration of US$ 12 million payable at closing, is expected to be funded through internal accruals. It is projected to be EPS-accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage. The deal is expected to close by the end of Q2 FY27, subject to customary closing conditions, including regulatory and antitrust approvals.
Aditya Kumar, Executive Director of Business Development at Strides, highlighted the significance of this acquisition as a milestone for the company’s ‘in Africa for Africa’ strategy. He noted that the transaction more than doubles Strides’ presence in the region, enhancing market penetration and consolidating leadership across key therapeutic areas.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Business Desk and reviewed by News Desk before publication.